Medical records of the products supplied in residences and hospitals to patients diagnosed with COVID-19

Remdesivir

Remdesivir (Veklury) Remdesivir (Veklury) | Some data indicated in the technical data sheet of the product: “it is in the investigational phase because it is still being studied” and “limited information is known on the safety and efficacy of using Veklury to treat people hospitalized for COVID-19”.

Tocilizumab

Tocilizumab (RoActemra) See product data sheet Tocilizumab (RoActemra) | is an expensive medication for rheumatoid arthritis from the Roche pharmaceutical company for which there is still no evidence of its safety and efficacy and, according to the laboratory, its frequent or very frequent side effects are “respiratory tract infection , pneumonia, abdominal pain, oral ulceration” among others.| Some data indicated in the product data sheet: Severe infections and in some fatal cases have been reported in patients receiving immunosuppressive agents including RoActemra | Viral reactivation (eg, hepatitis B virus) has been reported in RA patients who were receiving biological therapies.| Serious hypersensitivity reactions associated with RoActemra infusion have been reported.

Fentanyl

Fentanyl See product data sheet Fentanyl | According to its data sheet: The use of fentanyl in patients who have not previously received opioids has been associated with very rare cases ofsignificant respiratory depression or mortality when used as initial opioid therapy >.

Morfine

Morphine See product technical sheet Morphine | According to the technical date of the product, this medicine is contraindicated in patients with respiratory depression or severe obstructive respiratory disease.| The toxicological profile of morphine is similar to that of other opioid analgesics, although the effects appear more frequently.

Propofol

Propofol See product technical sheet Propofol | According to its data sheet, it can produce: Heart, circulatory or pulmonary insufficiency and hypovolemia | Propofol should not be administered to patients with advanced heart failure.

Cased

Cased Cased | An international multicenter study led by Vincenzo Russotto, from the School of Medicine and Surgery of the University of Milano-Bicocca (Italy), reveals that 45.2 percent of patients undergoing this procedure experienced at least one major clinical event, and one in three (32.8 percent) died in the ICU: Among the clinical events, the main one was cardiovascular instability, present in 42, 6 percent of patientss.